Compare Crispr Therapeutics AG (CRSP) vs MGM Resorts International (MGM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs MGM Resorts International — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while MGM Resorts International trades at $29.27 (market cap $7.55B). The key difference: MGM Resorts International is the larger of the two by market cap, and MGM Resorts International pays a 0.03% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and MGM Resorts International for 91 Days on average.
| CRSP | MGM | |
|---|---|---|
Market Cap | $4.88B | $7.55B |
Volume | 2,861,747 | 5,342,346 |
Sector | Health | Consumer Cyclical |
52-Week High | $73.97 | $50.69 |
52-Week Low | $44.34 | $29.27 |
Typical Hold Time | 77 Days | 91 Days |
Enterprise Value | $3.30B | $34.85B |
Dividend Yield | — | 0.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% on the day, reflecting a bearish technical trend amid weak financials. The company reported no revenue in 2025, with a net loss of $581.60M and negative profit margins, though it beat Q2 2026 EPS estimates. Analyst consensus remains bullish with a $67.83 price target, while recent news highlights upcoming clinical data readouts for its gene-editing therapies as potential catalysts.
The outlook hinges on pipeline execution, with key data expected by end-2026, but high cash burn and lack of revenue pose significant risks. Upside depends on successful clinical outcomes and commercialization of CASGEVY, while downside risks include trial failures and sustained losses.
MGM Resorts International (MGM) trades at $30.01, showing minimal daily movement. The stock is in a bearish technical trend with recent pressure following the collapse of a proposed acquisition by Barry Diller's People Inc. Fundamentally, revenue remains stable near $17.5 billion, but net income margin has compressed to 2.4% in 2025. The company maintains strong operating cash flow of $2.53 billion, though net cash flow was negative $338 million. Analyst sentiment is mixed but leans positive, with a consensus price target of $48.75 implying significant upside.
The investment outlook for MGM hinges on its ability to stabilize profitability and navigate deal uncertainty. The primary opportunity lies in the substantial discount to analyst targets, while risks include execution on potential acquisitions, competitive pressures in the gaming sector, and macroeconomic sensitivity. The stock's current valuation multiples, such as a P/E of 18.19, appear reasonable if earnings can recover.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →
